Siemens Healthineers AG SHL.DE
Composite 48/100; the shares have moved about 25% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 38/100 — a moderate mark against it.
Income ranks 67/100 — a moderate point in its favour. Growth ranks 55/100 — a slight point in its favour. Quality ranks 51/100 — a slight point in its favour.
Balance-sheet strength ranks 38/100 — a moderate mark against it. Momentum ranks 42/100 — a slight mark against it. Valuation ranks 50/100 — a slight mark against it.
What the company does Siemens Healthineers AG (SHL.DE) develops, manufactures, and sells diagnostic and therapeutic products across Imaging, Diagnostics, Varian, and Advanced Therapies segments. Its portfolio includes MRI, CT, X-ray systems, in-vitro diagnostics, oncology solutions, and workflow software for global healthcare providers.
Key financials Revenue declined -3.9% and EPS fell -4.3%, though margins remain robust: gross 38.0%, operating 12.8%, net 9.1%. ROE is 11.5%, ROA 4.1%, and ROCE 9.9%. Debt/equity is 0.84 with interest coverage of 7.77 and current ratio 1.10.
Stock health Momentum is weak: -22.32% over 12m and -22.67% below the 52-week high; RSI(14) is 68.20. Sideravia scores Valuation 61.7 (fairly valued) but Momentum 33.8 (weak) and Growth 24.5 (low). Dividend yield is 2.8% with a 53.8% payout ratio.
Price vs fair value The stock trades at a PREMIUM of 59.60% to our fair-value estimate and a discount of 21.60% to the analyst 12-month target. - Q3 earnings call highlighted diagnostics weakness and a cut to revenue outlook (The Wall Street Journal) - Forward P/E of 14.43 vs trailing 20.18 signals valuation concerns (Valuation percentile 61.7) - Piotroski F-Score 8/9 and Altman Z 1.83 indicate financial resilience but weak momentum persists (Sideravia)
Looking forward Forward PEG of 0.36 suggests potential undervaluation relative to growth, but near-term headwinds persist in diagnostics and oncology markets. Analysts target a 45.65 price, implying 21.60% upside from current levels.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.